Gracell Biotechnologies Inc. (GRCL) Cash Flow Quarterly

Gracell Biotechnologies Inc.

GRCL (NASDAQ)

(%)

Annual Quarterly

* (except for per share items) of CNY

Period Ending:	LTM (Last Twelve Months)	2023 (Q3) 09-30	2023 (Q2) 06-30	2023 (Q1) 03-31	2022 (Q4) 12-31	2022 (Q3) 09-30	2020 (Q4) 12-31	2019 (Q4) 12-31
Report Filing:	2023-09-30	2023-09-30	2023-08-14	2023-03-31	2023-04-25	2022-09-30	2021-04-23	1234
Net Income/Starting Line	-498	-68.15	-151.6	-152.4	-125.8	-179.2	-83.59	1234
Cash From Operating Activities	0	0	0	0	0	0	-63.95	1234
Depreciation and Amortization	0	0	0	0	0	0	9.35	1234
Deferred Income Tax	0	0	0	0	0	0	0	1234
Stock Based Compensation	0	0	0	0	0	0	0	1234
Other Non-Cash Items	498	68.15	151.6	152.4	125.8	179.2	0.677	1234
Changes in Working Capital	0	0	0	0	0	0	9.61	1234
Accounts Receivable	0	0	0	0	0	0	0	1234
Inventory	0	0	0	0	0	0	0	1234
Accounts Payable	0	0	0	0	0	0	0	1234
Deferred Revenue	0	0	0	0	0	0	0	1234
Other Working Capital	0	0	0	0	0	0	9.61	1234
Cash From Investing Activities	0	0	0	0	0	0	-12.15	1234
Investments in Property Plant and Equipment	0	0	0	0	0	0	-14.11	1234
Payments for Acquisitions	0	0	0	0	0	0	0	1234
Purchases of Securities	0	0	0	0	0	0	45.65	1234
Sales and Maturities of Investments	0	0	0	0	0	0	-43.69	1234
Other Investing Activities	0	0	0	0	0	0	0	1234
Cash From Financing Activities	0	0	0	0	0	0	693.1	1234
Debt Repayment	0	0	0	0	0	0	0	1234
Common Stock Issued	0	0	0	0	0	0	0	1234
Common Stock Repurchased	0	0	0	0	0	0	0	1234
Dividends Paid	0	0	0	0	0	0	0	1234
Other Financing Activities	0	0	0	0	0	0	693.1	1234
Effect of Forex Changes on Cash	0	0	0	0	0	0	-19.5	1234
Net Change in Cash	243.5	486.4	-161.5	-164.3	50.61	-196.1	597.5	1234
Cash at Beginning of Period	1,434	1,191	1,342	1,438	1,383	1,638	156.8	1234
Cash at End of Period	1,677	1,677	1,181	1,274	1,434	1,442	754.3	1234
Free Cash Flow	0	0	0	0	0	0	-78.06	1234
Operating Cash Flow	0	0	0	0	0	0	-63.95	1234
Capital Expenditure	0	0	0	0	0	0	-14.11	1234

Market is Open